-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Taizhou, November 17, 2021/PRNewswire/ - Jiangsu Ruike Biotechnology Co.
The new crown vaccine and adjuvant production base established by Ruike Biotech in Taizhou, Jiangsu Province is constructed in accordance with the current international GMP standards.
In the past 10 years, new adjuvant technologies have gradually emerged in the vaccine industry and are bringing profound changes to the industry
About Recombinant Two-Component New Coronary Pneumonia Vaccine (ReCOV)
In May 2020, Ruike Biotechnology cooperated with Jiangsu Province CDC and Taizhou Medical Park Management Committee to jointly develop a recombinant two-component COVID-19 vaccine (CHO cell)
About Ruike Bio
Ruike Biotechnology is an innovative vaccine company founded in 2011.
The information published in this press release may contain certain forward-looking statements
These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management on future affairs at the time the statement is made